How to buy Nabriva Therapeutics stock (NBRV)

Nabriva Therapeutics is a biotechnology & medical research business based in the US. Nabriva Therapeutics shares (NBRV) are listed on the NASDAQ and all prices are listed in US Dollars. Nabriva Therapeutics employs 39 staff and has a trailing 12-month revenue of around $36.5 million.

Our top picks for where to buy Nabriva Therapeutics stock

Buy Nabriva Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Nabriva Therapeutics stock price (NASDAQ: NBRV)

Use our graph to track the performance of NBRV stocks over time.

Nabriva Therapeutics shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$1.37
200-day moving average more info button	$1.67
Wall St. target price	$1.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-19.67

Is it a good time to buy Nabriva Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nabriva Therapeutics financials

Revenue TTM	$36.5 million
Gross profit TTM	$-10,226,000
Return on assets TTM	-65.2%
Return on equity TTM	-268.53%
Profit margin	-148.11%
Book value	$-1.36
Market Capitalization more info button	$4.5 million

TTM: trailing 12 months

Nabriva Therapeutics share dividends

We're not expecting Nabriva Therapeutics to pay a dividend over the next 12 months.

Have Nabriva Therapeutics's shares ever split?

Nabriva Therapeutics's shares were split on a 1:25 basis on 15 September 2022 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nabriva Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Nabriva Therapeutics shares which in turn could have impacted Nabriva Therapeutics's share price.

Nabriva Therapeutics share price volatility

Over the last 12 months, Nabriva Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nabriva Therapeutics's is 1.555. This would suggest that Nabriva Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Nabriva Therapeutics overview

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. .

Frequently asked questions

What percentage of Nabriva Therapeutics is owned by insiders or institutions?
Currently 0.968% of Nabriva Therapeutics shares are held by insiders and 8.777% by institutions. How many people work for Nabriva Therapeutics?
Latest data suggests 39 work at Nabriva Therapeutics. When does the fiscal year end for Nabriva Therapeutics?
Nabriva Therapeutics's fiscal year ends in December. Where is Nabriva Therapeutics based?
Nabriva Therapeutics's address is: 25-28 North Wall Quay, Dublin, Ireland, 1 What is Nabriva Therapeutics's ISIN number?
Nabriva Therapeutics's international securities identification number is: IE00BL53QQ85 What is Nabriva Therapeutics's CUSIP number?
Nabriva Therapeutics's Committee on Uniform Securities Identification Procedures number is: G63637105